cellsciences.com

Recombinant Human Interleukin-7

Catalog No: CRI108C **Size:** 1.0 mg

Lot Number: 7791-01S

Molecular Weight: 17.4 kDa, 152 amino acid residues

Purity: >98% as determined by SDS-PAGE and N-terminal sequence analyses.

Biological Activity: ED_{50} ≤0.5 ng/mL (≥2 x 10^6 units/mg). The biological activity is determined by measuring the dose dependent stimulation of IXN/2B cell proliferation. A concentration range of 0.1 to 10.0 ng/mL is effective for most *in vitro* applications. The optimal concentration should be determined for each specific application.

Formulation: Lyophilized, carrier-free

Sterility: Filtered prior to lyophilization through a 0.22 micron sterile filter.

Endotoxin: <0.1 ng/µg

Source: Recombinant human IL-7 is produced in *E. coli* and purified via sequential chromatography.

Reconstitution: We recommend that the vial be briefly centrifuged prior to opening to bring the contents to the bottom. Lyophilized hIL-7 may be reconstituted in PBS, H_2O, or other appropriate buffered solution to 0.1-1.0 mg/mL. These stock solutions should be apportioned into working aliquots and stored at ≤-20°C. Further dilution should be made in medium or buffered solution containing carrier protein, such as PBS with 0.1% BSA. (hIL-7 is supplied lyophilized and carrier-free for maximum flexibility in use; however, it is suggested that carrier protein be added to all reconstituted hIL-7 dilutions to ensure no loss in activity.)

Storage: Lyophilized hIL-7 should be stored at ≤+4°C, preferably desiccated. Store reconstituted hIL-7 at ≤-20°C. Keep freeze-thaw cycles to a minimum.

Stability: When stored properly, hIL-7 is stable for greater than one year lyophilized and greater than 3 months reconstituted.

References:

Ayyoub, M., S. Stevanovic, U. Sahin, P. Guillaume, C. Servis, D. Rimoldi, D. Valmori, P. Romero, J.C. Cerottini, H.G. Rammensee, M. Pfreundschuh, D. Speiser, and F. Levy (2002) Proteasome-assisted identification of a SSX-2-derived epitope recognized by tumor-reactive CTL infiltrating metastatic melanoma. J. Immunol. 168(4):1717-1722.

Butterfield, L.H., S.M. Jilani, N.G. Chakraborty, L.A. Bui, A. Ribas, V.B. Dissette, R. Lau, S.C. Gamradt, J.A. Glaspy, W.H. McBride, B. Mukherji and J.S. Economou (1998) Generation of melanoma-specific cytotoxic T lymphocytes by dendritic cells transduced with a MART-1 adenovirus. J. Immunol. 161(10):5607-5613.

Cosenza, L., E. Sweeny, and J.R. Murphy (1997) Disulfide bond assignment in human interleukin-7 by matrix-assisted laser desorption/ionization mass spectroscopy and site-directed cysteine to serine mutational analysis. J. Biol. Chem. 272(52):32995-33000.

Cell Sciences, Inc.
480 Neponset Street
Building 12A
Canton, MA 02021

Toll Free: 888 769-1246
Phone: 781 828-0610
Fax: 781 828-0542

E-mail: info@cellsciences.com
Web Site: www.cellsciences.com

Frost, P.A., L.H. Butterfield, V.B. Dissette, J.S. Economou, and B. Bonavida (2001) Immunosensitization of melanoma tumor cells to non-MHC Fas-mediated killing by MART-1-specific CTL cultures. J. Immunol. 166(5):3564-3573.

Le, P.T., K.L. Adams, N. Zaya, H.L. Mathews, W.J. Storkus, and T.M. Ellis (2001) Human thymic epithelial cells inhibit IL-15-and IL-2-driven differentiation of NK cells from the early human thymic progenitors. J. Immunol. 166(4):2194-2201.

Loparev, V., J. Parsons, J. Knight, J. Fanelli Panus, C. Ray, R. Buller, D. Pickup, and J. Esposito (1998) A third distinct tumor necrosis factor receptor of orthopoxviruses. Proc. Nat'l. Acad. Sci. 95(7):3786-3791.

Roth, M.D., Q.W. Cheng, A. Harui, S.K. Basak, K. Mitani, T.A. Low, and S.M. Kiertscher (2002) Helper-dependent adenoviral vectors efficiently express transgenes in human dendritic cells but still stimulate antiviral immune responses. J. Immunol. 169(8):4651-4656.

Cell Sciences, Inc.
480 Neponset Street
Building 12A
Canton, MA 02021

Toll Free: 888 769-1246
Phone: 781 828-0610
Fax: 781 828-0542

E-mail: info@cellsciences.com
Web Site: www.cellsciences.com